drug · small molecule

TRILEPTAL

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for epilepsy and seizure and 7 investigational indications.

targets

Sodium channel alpha subunit

all catalysts(0)

nothing on the calendar yet

Trials studying TRILEPTAL

phase1Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteerscompletedn=12
phase1Oxcarbazepine 600 mg Tablets Under Fasting Conditionscompletedn=60
phase1Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditionscompletedn=120
—Longitudinal Comparative Effectiveness of Bipolar Disorder Therapiesterminatedn=1,037,352
phase4The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.completedn=55

News(1)

Supernus, Indivior merge to beef up brain drug portfolio
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.
biopharma_dive · 11d ago

brand

TRILEPTAL

trade names

Oxcarbazepine, Oxtellar xr, Trileptal

generic

OXCARBAZEPINE

MOA

12.1 Mechanism of Action The pharmacological activity of TRILEPTAL is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine [ see Clinical Pharmacology (12.3) ]. The precise mechanism by which oxcarbazepine and MHD exert their anti-seizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug. No significant interactions of oxcarbazepine or MHD with brain neurotransmitter or modulator receptor sites have been demonstrated.

indication

1 INDICATIONS AND USAGE TRILEPTAL is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. TRILEPTAL is indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4-16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2-16 years ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 36m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

TRILEPTAL

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for epilepsy and seizure and 7 investigational indications.

targets

Sodium channel alpha subunit

all catalysts(0)

nothing on the calendar yet

Trials studying TRILEPTAL

phase1Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteerscompletedn=12
phase1Oxcarbazepine 600 mg Tablets Under Fasting Conditionscompletedn=60
phase1Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditionscompletedn=120
—Longitudinal Comparative Effectiveness of Bipolar Disorder Therapiesterminatedn=1,037,352
phase4The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.completedn=55

News(1)

Supernus, Indivior merge to beef up brain drug portfolio
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.
biopharma_dive · 11d ago

brand

TRILEPTAL

trade names

Oxcarbazepine, Oxtellar xr, Trileptal

generic

OXCARBAZEPINE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 36m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

TRILEPTAL

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TRILEPTAL

News(1)

Report a data issue

comments(0)

TRILEPTAL

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TRILEPTAL

News(1)

Report a data issue

comments(0)